<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04693663</url>
  </required_header>
  <id_info>
    <org_study_id>EHP</org_study_id>
    <nct_id>NCT04693663</nct_id>
  </id_info>
  <brief_title>Treatment of Residual Myopic Refraction After 6 Months on Pseudophakic Patients Using Relex-Smile</brief_title>
  <acronym>Relex-Smile</acronym>
  <official_title>Treatment of Residual Myopic Refraction After 6 Months on Pseudophakic Patients Using Relex-Smile</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eye Hospital Pristina Kosovo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eye Hospital Pristina Kosovo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess visual and refractive outcomes after laser vision&#xD;
      correction (LVC) - ReLex Smile to correct residual myopic refraction after 6 months of&#xD;
      pseudophakic (IOL) implantation.&#xD;
&#xD;
      Before SMILE YAG-Laser capsulotomy should be performed on all patients, regardless of&#xD;
      posterior capsule ossification, in pseudophakic patients with residual refraction. When the&#xD;
      YAG Laser is applied after the SMILE, there will be a diopter change.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The residual myopic refraction after 6 month on pseudophakic patients using Relex-Smile&#xD;
      surgery using VisuMax Femtosecond Laser.The residual myopic refractive power is between&#xD;
      -0.75D till -5.50D.The optical zone(lenticule diameter) and cap diameter were 6.5 and 7.5 mm&#xD;
      respectively.After dissection of both anterior and posterior planes, the lenticule was&#xD;
      extracted through 120 degree superior 3.5mm incision and marked with a sterile&#xD;
      marker(Viscot-Medster)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Actual">June 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>One group consisting of 40 eyes</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase of visual acuity</measure>
    <time_frame>6 months</time_frame>
    <description>Treatment of residual myopic refraction on Pseudophakic patients, was performed using ReLex Smile after 6 months.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pseudophakia</condition>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>ReLex Smile surgery</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Procedure/Surgery: Relex Smile The residual myopic refraction on Pseudophakic patients after 6 months using Relex-Smile surgery by VisuMax femtosecond laser. The residual refractive power was between -0.75D till -5.50D.The optical zone (lenticule diameter) and cap diameter were 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule was extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker(Viscot-Medster).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Relex-Smile surgery</intervention_name>
    <description>surgery using Relex-Smile</description>
    <arm_group_label>ReLex Smile surgery</arm_group_label>
    <other_name>Relex smile surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  residual myopic refraction -0.75d till -5.50D&#xD;
&#xD;
          -  complain visual acuity regarding residual myopic refraction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  active anterior segment pathologic features&#xD;
&#xD;
          -  previous corneal or anterior segment surgery&#xD;
&#xD;
          -  glaucoma&#xD;
&#xD;
          -  history of ocular inflammation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eye Hospital Pristina</name>
      <address>
        <city>Pristina</city>
        <zip>10000</zip>
        <country>Kosovo</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kosovo</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 25, 2020</study_first_submitted>
  <study_first_submitted_qc>December 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>August 29, 2021</last_update_submitted>
  <last_update_submitted_qc>August 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eye Hospital Pristina Kosovo</investigator_affiliation>
    <investigator_full_name>Dr. Faruk Semiz</investigator_full_name>
    <investigator_title>Head of Ophthalmology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudophakia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

